Concepedia
Statistics
Publications
7
Citations
114
H-Index
Active since
2008
Affiliations
Merck Serono S.A. (Switzerland)(Current)
Hôpital Beaujon
Kantonsspital St. Gallen
Institut Jules Bordet
University Hospital of Basel
N. Rejeb is an author at Merck Serono S.A. (Switzerland) specializing in medicine, cancer pharmacology, and pharmacology.
Publications per year
2008–2013
A phase I dose-escalation study of MSC1992371A, an oral inhibitor of aurora and other kinases, in advanced hematologic malignancies
Carlos Graux, Anne Sonet, Johan Maertens et al. · Leukemia Research · 2013 · 19 citations · Full text
Medicine, Hematology, Oncology +16
Safety and evidence of activity of MSC1936369, an oral MEK1/2 inhibitor, in patients with advanced malignancies.
Nadine Houédé, Sandrine Faivre, Ahmad Awada et al. · Journal of Clinical Oncology · 2011 · 19 citations
Medicine, Pharmacokinetics, Pharmacology +17
Phase I, Dose-Escalation Study of 2 Dosing Regimens of AS703569, An Inhibitor of Aurora and Other Kinases, Administered Orally in Patients with Advanced Hematological Malignancies
Anne Sonet, Carlos Graux, Johan Maertens et al. · Blood · 2008 · 18 citations
Medicine, Oncology, Pharmacology +17
A phase l study of three different dosing schedules of the oral aurora kinase inhibitor MSC1992371A in patients with solid tumors
Monica Mita, Michael S. Gordon, N. Rejeb et al. · Targeted Oncology · 2013 · 17 citations
Medicine, Oncology, Pharmacology +14
A phase I schedule dependency study of the aurora kinase inhibitor MSC1992371A in combination with gemcitabine in patients with solid tumors
Éric Raymond, Joachim Alexandre, Sandrine Faivre et al. · Investigational New Drugs · 2013 · 16 citations
Medicine, Oncology, Pharmacology +13
1–5 of 7